TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01284686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subthalamo-cortical loops stimulation in a one-sided and bipolar way
Description: Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
Study: NCT01264822

Intervention type: DRUG
Intervention: Rabeprazole Sodium
Description: The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg.
Study: NCT05933408

Intervention type: DIAGNOSTIC_TEST
Intervention: TREM-1
Description: The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
Study: NCT03848728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEARCH Youth combination intervention
Description: * Administration of life-stage assessment tool~* Structured choice clinic access~* Rapid feedback of VL results~* Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information
Study: NCT00114413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Description: Used for both regular asthma control and as a rescue inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroids
Description: Used for both regular asthma control and as a rescue inhaler

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eNO measurement
Description: measured by Aerocrine® NIOX device
Study: NCT02170792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: Low, medium or high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: Low, medium or high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 150mg
Study: NCT02414737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitrophin alfa
Description: use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
Study: NCT01749904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOL-303259-X
Description: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
Study: NCT00581815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton-decoupled 31P MRS at 1.5T
Description: The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1H Spectroscopy at 1.5T and 3T
Description: The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
Study: NCT00014131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: therapeutic autologous dendritic cells.
Description: Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
Study: NCT01306097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: 10mg daily for under 1 years old children and 20mg daily for above 1 years old children
Study: NCT00379743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health coordinator (or patient navigator)
Description: Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials only
Description: A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
Study: NCT05316194

Intervention type: OTHER
Intervention: Digital treatment for hip and knee osteoarthritis
Description: The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program.
Study: NCT04385420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo film-coated tablet administered via oral route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo film-coated tablet administered via oral route
Study: NCT01137968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imetelstat
Description: 9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
Study: NCT02289612

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yellow Mustard Gum Fibre

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yellow Mustard Gum Fibre

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yellow Mustard Gum Fibre

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yellow Mustard Gum Fibre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Mustard Gum Fibre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Mustard Gum Fibre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Flaxseed Gum Fibre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Flaxseed Gum Fibre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fenugreek Gum Fibre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fenugreek Gum Fibre
Study: NCT04388241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Balance Program
Description: The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
Study: NCT03215810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating Lymphocytes (TIL)
Description: Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating Lymphocyte Therapy
Description: On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL2)
Description: Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
Study: NCT02931071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: G-CSF (12 μg/Kg/12 h) 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
Study: NCT01771328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone acetate
Description: Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
Study: NCT00790764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESENDO
Description: For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
Study: NCT02593409

Intervention type: DRUG
Group type: OTHER
Intervention: TDF/FTC
Description: All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
Study: NCT04308772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Physiotherapy
Description: Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
Study: NCT04355910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restriction
Description: Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat.
Study: NCT01814202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTM202

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04600232

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Alere TB-LAM
Description: Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
Study: NCT00558337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
Study: NCT01333163

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human GLP-1 (7-36) amide
Description: 2 hour IV infusion, 1,5pmol/min/kg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Isotone NaCl
Description: 2 hours IV infusion.
Study: NCT01619150

Intervention type: DRUG
Group type: OTHER
Intervention: Etoricoxib, followed by placebo (matching tablet, without active ingredient)
Description: Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (matching tablet, without active ingredient), followed by etoricoxib
Description: Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
Study: NCT02095951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (ELT)
Description: Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol lock therapy (ELT)
Description: Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
Study: NCT05019378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF treatment
Description: autologous SVF (10E8 cells)
Study: NCT02851927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini Thoracoscopy
Description: Pleural biopsy using rigid mini thoracoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SemiRigid Thoracoscopy
Description: Pleural biopsy using semirigid thoracoscope
Study: NCT02938533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
Study: NCT02729428

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan
Study: NCT02208999

Intervention type: DEVICE
Intervention: Neurostimulator Precision
Description: All patients included must have been implanted with the neurostimulator Precision
Study: NCT02652871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days.
Study: NCT03293693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5 g beta-glucan
Description: Dietary cross-over study with beta-glucan fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.5 g beta-glucan
Description: Dietary cross-over study with beta-glucan fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8 g beta-glucan
Description: Dietary cross-over study with beta-glucan fiber
Study: NCT00671944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Low protein diet for 6.5 weeks
Study: NCT02369770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stretching and active movement training
Description: A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stretching and active movement training
Description: A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.